Simvastatin alleviates diabetes-induced VEGF-mediated nephropathy via the modulation of Ras signaling pathway

Renal Failure

Volumn 30, Issue 5, 2008, Pages 557-565

  Ho, Cheng ^a   Hsu, Yen Chen ^b   Tseng, Ching Cheng ^a   Wang, Feng Sheng ^c   Lin, Chun Liang ^a,c   Wang, Jeng Yi ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Diabetes; Ras; Simvastatin; Vascular endothelial growth factor (VEGF)

Indexed keywords

GLUCOSE; MANUMYCIN; MANUMYCIN A; MESSENGER RNA; MEVINOLIN; RAS PROTEIN; SIMVASTATIN; VASCULOTROPIN;

ALBUMINURIA; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; IMMUNOHISTOLOGY; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

ANIMALS; CELLS, CULTURED; DIABETIC NEPHROPATHIES; GLOMERULAR MESANGIUM; POLYENES; POLYUNSATURATED ALKAMIDES; RAS PROTEINS; RATS; SIGNAL TRANSDUCTION; SIMVASTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45749129025     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802064457     Document Type: Article

References (29)

1. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8:952-959.
2. Lee HB, Seo JY, Yu MR, Uh ST, Ha H. Radical approach to diabetic nephropathy. Kidney Int Suppl. 2007;106:S67-S70.
3. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia. 2000;43:1205-1223.
4. Tilton RG, Kawamura T, Chang KC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest. 1997;99:2192-2202.
5. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48:2229-2239.
6. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 2001;12:993-1000.
7. Flyvbjerg A, Dagnaes-Hansen F, de Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002;51:3090-3094.
8. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol. 2006;17:3093-3104.
9. Ludwig S, Shen GX. Statins for diabetic cardiovascular complications. Curr Vasc Pharmacol. 2006;4:245-251.
10. Kurata, H. The preventive effect of an HMG-CoA reductase inhibitor, pravastatin, on diabetic nephropathy in streptozotocin-diabetic rats. Jikeikai Med J. 1994;41:219-230.
11. Danesh FR, Sadeghi MM, Amro N. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA. 2002;99:8301-8305.
12. Lin CL, Wang FS, Kuo YR. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int. 2006;69:1593-1600.
13. Obrosova IG, Minchenko AG, Vasupuram R. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52:864-871.
14. Yamakawa M, Liu LX, Date T, et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res. 2003;93:664-673.
15. Mooradian AD, Haas MJ. Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats. Am J Ther. 2007;14:41-45.
16. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16:3748-3754.
17. Qin J, Zhang Z, Liu J, et al. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int. 2003;64:565-571.
18. Liu E, Morimoto M, Kitajima S, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol. 2007;18:2094-2104.
19. Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007;18:539-550.
20. Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma JX. Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol. 2006;17:475-486.
21. Zeng L, Xu H, Chew TL, et al. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J. 2005;19:1845-1847.
22. Chen J, Braet F, Brodsky S, et al. VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. Am J Physiol Cell Physiol. 2001;282:C1053-C1063.
23. Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003;18:265-272.
24. Misra A, Kumar S, Kishore Vikram N, Kumar A. The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am J Cardiovasc Drugs. 2003;3:325-338.
25. Feleszko W, Balkowiec EZ, Sieberth E, et al. Lovastatin and tumor necrosis factor-? exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer. 1999;81:560-567.
26. Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its antiangiogenic effect. FEBS Lett. 2001;495:159-166.
27. Wojciak-Stothard B, Potempa S, Eichholtz T, Ridley AJ. Rho and Rac but not Cdc42 regulate endothelial cell permeability. J Cell Sci. 2001;114:1343-1355.
28. Jacobson JR, Dudek SM, Birukov KG, et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004;30:662-670.
29. Fujii M, Inoguchi T, Maeda Y, et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by down regulating NOX4 in db/db mice. Kidney Int. 2007;72:473-480.